Published Date: 17 Feb 2023
BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...
Read Full NewsA leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.
(Refiles to remove extraneous word years from first paragraph)
The Moderna vaccine will likely be available in Europe long before the US.
Saline lavage, alone or combined with intrapleural enzyme therapy, confers no clinically meaningful advantage over intrapleural enzyme therapy alone in patients with pleural infection.
Many doctors facing racism from patients stay silent, doubting they’ll be heard. Experts share strategies for handling bias when institutions fall short.
In patients with HIV‑1 infection and virologic suppression, switching to an investigational regimen of doravirine plus islatravir shows efficacy and safety similar to standard ART regimens.
Peak anti-hepatitis B surface antibody levels predicted increased viral protection in HIV, a French study shows.
1.
Dense breasts: What it means and what women can do about screening
2.
The majority of cancer medications that receive expedited approval end up failing confirmatory trials.
3.
The risk of lung cancer recurrence is linked to hypoxemia brought on by sleep apnea.
4.
Formaldehyde Causes More Cancer Than Any Other Toxic Air Pollutant
5.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
1.
Cardio-Oncology: Managing Heart Failure in Survivors of Cancer
2.
Optimizing Cancer Care: Multidisciplinary Approaches and Supportive Strategies
3.
Decoding Hamartomas: Understanding Their Causes and Symptoms
4.
Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections
5.
Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Efficient Management of First line ALK-rearranged NSCLC
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation